Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: Phase 1/2 study

Journal of Infectious Diseases

Volumn 182, Issue 6, 2000, Pages 1774-1779

  Shearer, William T ^a   Israel, Robert J ^b   Starr, Stuart ^c   Fletcher, Courtney V ^d   Wara, Diane ^e   Rathore, Mobeen ^h   Church, Joseph ^f   DeVille, Jaime ^g   Fenton, Terence ⁱ   Graham, Bobbie ^j   Samson, Pearl ^k   Staprans, Silvija ^l   McNamara, James ^m   Moye, John ⁿ   Maddon, Paul J ^b   Olson, William C ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b A Subsidiary of Lantheus Holdings   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

ⁱ FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^j Statistical and Data Management Cente   (United States)

^k HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^l EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁿ EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD4 IMMUNOGLOBULIN; IMMUNOGLOBULIN G2; RECOMBINANT PROTEIN; VIRUS RNA;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADOLESCENT; ANTI-HIV AGENTS; CD4 IMMUNOADHESINS; CHILD; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOCYTES, MONONUCLEAR; MALE; RECOMBINANT FUSION PROTEINS; RNA, VIRAL; VIRAL LOAD;

EID: 0033712475     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/317622     Document Type: Article

References (16)

1. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain
2. The safety and pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: A phase 1 study
3. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex: A phase I-II escalating dosage trial
4. The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia
5. Phase I study of high-dose, intravenous rsCD4 in subjects with advanced HIV-1 infection
6. Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex
7. Transport of recombinant human CD4-immunoglobulin G across the human placenta: Pharmacokinetics and safety in six mother-infant pairs in AIDS clinical trial group protocol 146
8. Chemokine receptors as HIV-I coreceptors: Roles in viral entry, tropism, and disease
9. Expression and characterization of CD4-IgG2, a novel heterotetramer which neutralizes primary HIV-1 isolates
10. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG2
11. Effective ex vivo neutralization of plasma HIV-1 by recombinant immunoglobulin molecules
12. CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates
13. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage
14. Single-dose safety, pharmacology and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults
15. Pharmacokinetics. 2d ed.
16. DAIDS virology manual for HIV laboratories